Novo Nordisk reported an increase in operating profit of 25% in Danish kroner and 29% at constant exchange rates, with sales growth across US and International Operations. Sales within Diabetes and Obesity care increased by 16%, driven by Obesity care growth of 56% and GLP-1 diabetes sales growth of 8%. Sales outlook for 2025 has been adjusted to 8-14% at CER. Lars Fruergaard Jørgensen stated that the company is taking measures to sharpen commercial execution and ensure efficiencies in cost base. An earnings call will be held on 6 August 2025 at 13.00 CET, with investors able to listen in via a link on Novo Nordisk’s website.

In H1 2025, Novo Nordisk reported a 16% increase in net sales and a 25% increase in operating profit. The company’s net profit increased by 22%, with diluted earnings per share also increasing. Despite strong first-half results, the company has lowered its full-year outlook due to lower growth expectations for GLP-1 treatments in the second half of 2025. Novo Nordisk’s president and CEO, Lars Fruergaard Jørgensen, expressed confidence in the company’s future growth opportunities under the leadership of Maziar Mike Doustdar.

Novo Nordisk, a leading global healthcare company founded in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases, particularly in the field of diabetes. With approximately 78,400 employees in 80 countries, Novo Nordisk markets its products in around 170 countries. The company’s B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange. For more information, visit Novo Nordisk’s website or social media platforms.

For further information, media contacts include Ambre James-Brown and Liz Skrbkova, while investor relations contacts include Jacob Martin Wiborg Rode, Sina Meyer, Max Ung, Alex Bruce, and Christoffer Sho Togo Tullin. Novo Nordisk’s latest company announcement is No 20 / 2025.

Read more at GlobeNewswire: Novo Nordisk’s sales increased by 16% in Danish kroner and